IP Library › Granted Patent US 7,663,017
Granted Patent B2
US 7,663,017 · App. 10/882,241 · Granted Feb 16, 2010

Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications

Assignee: Institut Pasteur
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,663,017
App. No.
10/882,241
Granted
Feb 16, 2010
Kind
B2
Abstract

The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2 + HLA-DR1 + β2m°IAβ°. The invention also relates to methods of using a transgenic mouse of the invention.

Claims (14)

1. A transgenic mouse comprising:

a) a disrupted H2 class I gene;

b) a disrupted H2 class II gene;

c) a functional HLA-A2 transgene; and

d) a functional HLA-DR1 transgene,

wherein the transgenic mouse has the genotype HLA-A2 + HLA-DR1 1 β2m°IAβ° and the phenotypes of (i) complete restriction by the HLA transgenes, and (ii) complete absence of immune responses restricted by the H2 genes.

2. The transgenic mouse according to claim 1 , wherein the HLA-A2 transgene comprises the HLA-A2 sequence provided by SEQ ID NO: 1 and the HLA-DR1 transgene comprises the HLA-DR1 sequences provided by SEQ ID NOs: 2 and 3.

3. An isolated transgenic mouse cell comprising:

a) a disrupted H2 class I gene;

b) a disrupted H2 class II gene;

c) a functional HLA-A2 transgene; and

d) a functional HLA-DR1 transgene

wherein the transgenic mouse has the genotype HLA-A2 + HLA-DR1 + β2m°IAβ° and the phenotypes of (i) complete restriction by HLA transgenes, and (ii) complete absence of immune responses restricted by the H2 genes.

4. The transgenic mouse cell according to claim 3 , wherein the HLA-A2transgene comprises the HLA-A2 sequence provided by SEQ ID NO:1 and the HLA-DR1 transgene comprises the HLA-DR1 sequences provided by SEQ ID NOs: 2 and 3.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2010
From: LONE, YU-CHUN; PAJOT, ANTHONY; AURIAULT, CLAUDE; PANCRE, VERONIQUE; LEMONNIER, FRANCOIS
To: INSTITUT PASTEUR; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Reel/Frame 024411/0964 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2008
From: LONE, YU-CHUN; PAJOT, ANTHONY; AURIAULT, CLAUDE; PANCRE, VERONIQUE; LEMONNIER, FRANCOIS
To: INSTITUT PASTEUR
Reel/Frame 021385/0141 →
Continuity (2)
Provisional Application 6049094500 · Jul 30, 2003
Related Publication 20050114910A1 · May 26, 2005